Lamivudine-13C,15N2,d2

• UNSPSC Description:

  Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase[1][2][3][4].

• Target Antigen:

  HBV; HIV; Isotope-Labeled Compounds; Reverse Transcriptase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Others

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  OC([2H])([2H])[C@@H]1O[C@H]([15N]2C=CC(N)=[15N][13C]2=O)CS1

• Molecular Weight:

  234.25

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26(1):216-25. |[3]Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3(4):545-50. |[4]Mdanda S, et al. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay Drug Dev Technol. 2019 Oct;17(7):322-329.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported